TABLE 96New base case with modified caregiver utility

ADNew base caseNew base case with improved carer utility after institutionalisation
Cost (£)aCarer QALYsaTotal QALYsaCost (£)aCarer QALYsaTotal QALYsaICER (£)
Mild−35630.0160.164−3563−0.0100.138−25,844
Moderate−17630.0110.111−1763−0.0100.091−19,399
a

Indicates differences between treatment options.

From: 5, Assessment of industry submissions to NICE

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.